{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:55:35Z","timestamp":1776142535588,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In recent years, neoadjuvant chemoimmunotherapy (NICT) has become a research focus in the treatment of esophageal cancer. This study aims to evaluate the predictive value of tumor volume changes before and after NICT for prognosis in patients with operable esophageal squamous cell carcinoma (ESCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective study included 163 patients with histologically confirmed ESCC from two medical centers between October 1, 2020, and October 1, 2022. All patients received NICT before undergoing radical esophagectomy. Based on pre- and post\u2212treatment CT images, we delineated and calculated the volume of the esophageal tumor. The rate of tumor volume change was then analyzed for its association with patient prognosis. The study endpoints were overall survival (OS), disease\u2212free survival (DFS) and progression\u2212free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariate regression analysis indicated that tumor location, number of NICT cycles, and tumor volume change rate were independent influencing factors for both DFS and PFS. The interval between NICT completion and surgery, along with tumor volume change rate, were independent factors for OS. Significant tumor volume reduction served as a predictor of favorable prognosis, demonstrating certain predictive value for long-term survival in patients. Surgery performed within 6 weeks of neoadjuvant therapy was significantly associated with longer OS, while DFS and PFS also showed a trend toward improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The change in tumor volume before and after neoadjuvant therapy is an independent prognostic factor for esophageal cancer patients receiving NICT. Additionally, performing radical surgery as soon as possible after completing neoadjuvant therapy is associated with improved survival outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1772722","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:30Z","timestamp":1776140490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between tumor volume changes during neoadjuvant chemoimmunotherapy and survival outcomes in esophageal squamous cell carcinoma: a multicenter study"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-020-01237-x","article-title":"Epidemiology of esophageal cancer: update in global trends, etiology and risk factors","volume":"13","author":"Uhlenhopp","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.05.01","article-title":"Esophageal cancer: epidemiology, risk factors and screening","volume":"33","author":"Li","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"B3","article-title":"CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events","volume":"13","author":"Tian","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21037\/atm.2017.11.28","article-title":"Advances in radiotherapy for esophageal cancer","volume":"6","author":"Deng","year":"2018","journal-title":"Ann Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2020.100041","article-title":"Current status and future perspective of immunotherapy in gastrointestinal cancers","volume":"1","author":"Lu","year":"2020","journal-title":"Innovation Camb"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.05.66","article-title":"Adjuvant chemotherapy is associated with improved survival in patients with nodal metastases after neoadjuvant therapy and esophagectomy","volume":"11","author":"Drake","year":"2019","journal-title":"J Thorac Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/0284186x.2017.1415458","article-title":"Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer","volume":"57","author":"Nurmi","year":"2018","journal-title":"Acta Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s145063","article-title":"Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis","volume":"11","author":"Ma","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31312","article-title":"Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis","volume":"143","author":"Chan","year":"2018","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox002","article-title":"Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer","volume":"30","author":"Zhang","year":"2017","journal-title":"Dis Esophagus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.734581","article-title":"Neoadjuvant therapy for locally advanced esophageal cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052542","article-title":"Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117448","article-title":"Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002472","article-title":"Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival","volume":"9","author":"de Klerk","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.medj.2024.05.008","article-title":"Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial","volume":"5","author":"He","year":"2024","journal-title":"Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.836338","article-title":"Safety and feasibility of esophagectomy following combined immunotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score matching analysis","volume":"13","author":"Hong","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doac031","article-title":"Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China","volume":"35","author":"Yang","year":"2022","journal-title":"Dis Esophagus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2024-2107","article-title":"Comparison of neoadjuvant chemotherapy plus immunotherapy versus chemoradiotherapy for esophageal squamous cell carcinoma patients: efficacy and safety outcomes","volume":"17","author":"Shi","year":"2025","journal-title":"J Thorac Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39778","article-title":"Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis","volume":"5","author":"Ge","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.010","article-title":"Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer","volume":"12","author":"Wald","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s246500","article-title":"Intratreatment tumor volume change during definitive chemoradiotherapy is predictive for treatment outcome of patients with esophageal carcinoma","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doae059","article-title":"Esophagectomy after definitive chemoradiation in esophageal cancer: a safe therapeutic strategy","volume":"37","author":"van Geffen","year":"2024","journal-title":"Dis Esophagus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.05.016","article-title":"Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma","volume":"5","author":"Alsina","year":"2024","journal-title":"Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study","volume":"10","author":"Metges","year":"2025","journal-title":"ESMO Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13014-022-02074-7","article-title":"Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy","volume":"17","author":"Adrian","year":"2022","journal-title":"Radiat Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26380","article-title":"Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma","volume":"42","author":"Flukes","year":"2020","journal-title":"Head Neck"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1066896919855760","article-title":"Residual cancer volume predicts clinical outcome in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy","volume":"27","author":"Nakao","year":"2019","journal-title":"Int J Surg Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.04.08","article-title":"Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy","volume":"8","author":"Chen","year":"2016","journal-title":"J Thorac Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.09.118","article-title":"Radiologic response to neoadjuvant treatment predicts histologic response in thymic epithelial tumors","volume":"12","author":"Johnson","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"666","DOI":"10.21037\/atm-22-2418","article-title":"The predictive value of tumor volume reduction ratio on three-dimensional endorectal ultrasound for tumor response to chemoradiotherapy for locally advanced rectal cancer","volume":"10","author":"Chen","year":"2022","journal-title":"Ann Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-024-03845-3","article-title":"Cryoablation in extra-abdominal desmoid tumors: a 10-year experience in pediatric and young adult patients","volume":"47","author":"Shaikh","year":"2024","journal-title":"Cardiovasc Intv Radiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-019-0155-1","article-title":"Challenges in assessing solid tumor responses to immunotherapy","volume":"27","author":"Chai","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41747-019-0134-1","article-title":"Imaging of tumour response to immunotherapy","volume":"4","author":"Dromain","year":"2020","journal-title":"Eur Radiol Exp"},{"key":"B40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/jcm15020814","article-title":"Immune checkpoint inhibitor-associated myocarditis: risk, diagnosis, and clinical impact","volume":"15","author":"Mauriello","year":"2026","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jjco\/hyx154","article-title":"Immune checkpoint inhibitor-related myocarditis","volume":"48","author":"Tajiri","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goaf060","article-title":"Delayed surgery for more than 9 weeks induces worse survival outcomes in locally advanced rectal cancer patients with poor response to neoadjuvant chemoradiotherapy: a propensity score matched cohort study","volume":"13","author":"Wang","year":"2025","journal-title":"Gastroenterol Rep Oxf"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000901","article-title":"Relationship of lymph node micrometastasis and micropapillary component and their joint influence on prognosis of patients with stage I lung adenocarcinoma","volume":"41","author":"Dai","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v17.i10.107741","article-title":"Assessment of the status of micrometastasis and tumor spillage among the patients undergoing thoracoscopic esophagectomy for carcinoma esophagus","volume":"17","author":"Shukla","year":"2025","journal-title":"World J Gastrointest Surg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1642765","article-title":"Strategies of neoadjuvant therapy in esophageal cancer: a study on the effects of treatment frequency and surgery interval","volume":"15","author":"Lv","year":"2025","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1581530","article-title":"Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18is2.958","article-title":"Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma","author":"Hotte","year":"2011","journal-title":"Curr Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-023-01430-8","article-title":"Novel strategies for cancer immunotherapy: counter-immunoediting therapy","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semcancer.2021.03.002","article-title":"Therapeutic applications of the cancer immunoediting hypothesis","volume":"78","author":"Desai","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-021-08747-y","article-title":"Evaluating the effect of neoadjuvant chemotherapy for esophageal cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study","volume":"21","author":"Taniyama","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1772722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:30Z","timestamp":1776140490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1772722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1772722"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1772722","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1772722"}}